1062 related articles for article (PubMed ID: 15800326)
1. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
Dudley ME; Wunderlich JR; Yang JC; Sherry RM; Topalian SL; Restifo NP; Royal RE; Kammula U; White DE; Mavroukakis SA; Rogers LJ; Gracia GJ; Jones SA; Mangiameli DP; Pelletier MM; Gea-Banacloche J; Robinson MR; Berman DM; Filie AC; Abati A; Rosenberg SA
J Clin Oncol; 2005 Apr; 23(10):2346-57. PubMed ID: 15800326
[TBL] [Abstract][Full Text] [Related]
2. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.
Dudley ME; Yang JC; Sherry R; Hughes MS; Royal R; Kammula U; Robbins PF; Huang J; Citrin DE; Leitman SF; Wunderlich J; Restifo NP; Thomasian A; Downey SG; Smith FO; Klapper J; Morton K; Laurencot C; White DE; Rosenberg SA
J Clin Oncol; 2008 Nov; 26(32):5233-9. PubMed ID: 18809613
[TBL] [Abstract][Full Text] [Related]
3. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.
Nguyen LT; Saibil SD; Sotov V; Le MX; Khoja L; Ghazarian D; Bonilla L; Majeed H; Hogg D; Joshua AM; Crump M; Franke N; Spreafico A; Hansen A; Al-Habeeb A; Leong W; Easson A; Reedijk M; Goldstein DP; McCready D; Yasufuku K; Waddell T; Cypel M; Pierre A; Zhang B; Boross-Harmer S; Cipollone J; Nelles M; Scheid E; Fyrsta M; Lo CS; Nie J; Yam JY; Yen PH; Gray D; Motta V; Elford AR; DeLuca S; Wang L; Effendi S; Ellenchery R; Hirano N; Ohashi PS; Butler MO
Cancer Immunol Immunother; 2019 May; 68(5):773-785. PubMed ID: 30747243
[TBL] [Abstract][Full Text] [Related]
4. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.
Chandran SS; Somerville RPT; Yang JC; Sherry RM; Klebanoff CA; Goff SL; Wunderlich JR; Danforth DN; Zlott D; Paria BC; Sabesan AC; Srivastava AK; Xi L; Pham TH; Raffeld M; White DE; Toomey MA; Rosenberg SA; Kammula US
Lancet Oncol; 2017 Jun; 18(6):792-802. PubMed ID: 28395880
[TBL] [Abstract][Full Text] [Related]
5. Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy.
Nissani A; Lev-Ari S; Meirson T; Jacoby E; Asher N; Ben-Betzalel G; Itzhaki O; Shapira-Frommer R; Schachter J; Markel G; Besser MJ
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33990415
[TBL] [Abstract][Full Text] [Related]
6. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
[TBL] [Abstract][Full Text] [Related]
7. Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma.
Wallen H; Thompson JA; Reilly JZ; Rodmyre RM; Cao J; Yee C
PLoS One; 2009; 4(3):e4749. PubMed ID: 19270751
[TBL] [Abstract][Full Text] [Related]
8. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma.
Pilon-Thomas S; Kuhn L; Ellwanger S; Janssen W; Royster E; Marzban S; Kudchadkar R; Zager J; Gibney G; Sondak VK; Weber J; Mulé JJ; Sarnaik AA
J Immunother; 2012 Oct; 35(8):615-20. PubMed ID: 22996367
[TBL] [Abstract][Full Text] [Related]
10. Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation.
Tseng J; Citrin DE; Waldman M; White DE; Rosenberg SA; Yang JC
Cancer; 2014 May; 120(9):1426-32. PubMed ID: 24474396
[TBL] [Abstract][Full Text] [Related]
11. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients.
Ellebaek E; Iversen TZ; Junker N; Donia M; Engell-Noerregaard L; Met Ö; Hölmich LR; Andersen RS; Hadrup SR; Andersen MH; thor Straten P; Svane IM
J Transl Med; 2012 Aug; 10():169. PubMed ID: 22909342
[TBL] [Abstract][Full Text] [Related]
12. Adoptive cell transfer therapy.
Dudley ME; Rosenberg SA
Semin Oncol; 2007 Dec; 34(6):524-31. PubMed ID: 18083376
[TBL] [Abstract][Full Text] [Related]
13. Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors.
Hirai I; Funakoshi T; Kamijuku H; Fukuda K; Mori M; Sakurai M; Koda Y; Kato J; Mori T; Watanabe N; Noji S; Yaguchi T; Iwata T; Ohta S; Fujita T; Tanosaki R; Handa M; Okamoto S; Amagai M; Kawakami Y
Cancer Sci; 2021 Aug; 112(8):3163-3172. PubMed ID: 34101300
[TBL] [Abstract][Full Text] [Related]
14. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.
Besser MJ; Shapira-Frommer R; Itzhaki O; Treves AJ; Zippel DB; Levy D; Kubi A; Shoshani N; Zikich D; Ohayon Y; Ohayon D; Shalmon B; Markel G; Yerushalmi R; Apter S; Ben-Nun A; Ben-Ami E; Shimoni A; Nagler A; Schachter J
Clin Cancer Res; 2013 Sep; 19(17):4792-800. PubMed ID: 23690483
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases.
Mehta GU; Malekzadeh P; Shelton T; White DE; Butman JA; Yang JC; Kammula US; Goff SL; Rosenberg SA; Sherry RM
J Immunother; 2018 Jun; 41(5):241-247. PubMed ID: 29672342
[TBL] [Abstract][Full Text] [Related]
16. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma.
Rosenberg SA; Yang JC; Robbins PF; Wunderlich JR; Hwu P; Sherry RM; Schwartzentruber DJ; Topalian SL; Restifo NP; Filie A; Chang R; Dudley ME
J Immunother; 2003; 26(5):385-93. PubMed ID: 12973027
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response.
Besser MJ; Itzhaki O; Ben-Betzalel G; Zippel DB; Zikich D; Kubi A; Brezinger K; Nissani A; Levi M; Zeltzer LA; Ben-Nun A; Asher N; Shimoni A; Nagler A; Markel G; Shapira-Frommer R; Schachter J
Mol Carcinog; 2020 Jul; 59(7):736-744. PubMed ID: 32250515
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.
Dudley ME; Wunderlich JR; Yang JC; Hwu P; Schwartzentruber DJ; Topalian SL; Sherry RM; Marincola FM; Leitman SF; Seipp CA; Rogers-Freezer L; Morton KE; Nahvi A; Mavroukakis SA; White DE; Rosenberg SA
J Immunother; 2002; 25(3):243-51. PubMed ID: 12000866
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.
Dafni U; Michielin O; Lluesma SM; Tsourti Z; Polydoropoulou V; Karlis D; Besser MJ; Haanen J; Svane IM; Ohashi PS; Kammula US; Orcurto A; Zimmermann S; Trueb L; Klebanoff CA; Lotze MT; Kandalaft LE; Coukos G
Ann Oncol; 2019 Dec; 30(12):1902-1913. PubMed ID: 31566658
[TBL] [Abstract][Full Text] [Related]
20. Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.
Moore T; Wagner CR; Scurti GM; Hutchens KA; Godellas C; Clark AL; Kolawole EM; Hellman LM; Singh NK; Huyke FA; Wang SY; Calabrese KM; Embree HD; Orentas R; Shirai K; Dellacecca E; Garrett-Mayer E; Li M; Eby JM; Stiff PJ; Evavold BD; Baker BM; Le Poole IC; Dropulic B; Clark JI; Nishimura MI
Cancer Immunol Immunother; 2018 Feb; 67(2):311-325. PubMed ID: 29052782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
